Parathyroid carcinoma : clinical course, diagnosis and management by Captur, Gabriella et al.
Malta Medical Journal    Volume 22   Issue 02   2010 25
Gabriella Captur, Lisa Micallef Grimaud, Alexandra Betts, 
James Degaetano, Alex Attard, Josanne Vassallo
Case Report
Parathyroid carcinoma: 
clinical course, diagnosis and management
Keywords
Parathyroid gland, carcinoma, gene, parathyroid hormone, 
calcium
* corresponding author
Abstract
Parathyroid carcinoma is a rare cause of primary 
hyperparathyroidism often resulting in severe hypercalcaemia. It 
tends to follow a rather aggressive course with a high propensity 
for locoregional spread and distant metastasis. En bloc resection 
is the mainstay of treatment, with surgery also playing a role in the 
palliation of hypercalcaemia for recurrent and metastatic disease. 
While adjuvant chemotherapy and radiotherapy have shown 
disappointing outcomes, bisphosphonates and calcimimetic agents 
are effective in the management of recalcitrant hypercalcaemia in 
parathyroid carcinoma. 
We report a case of parathyroid carcinoma in a lady who 
initially presented with a neck mass, severe hypercalcaemia, a bony 
swelling over the shin and elevated parathyroid hormone levels. 
The diagnosis was confirmed histologically following a thyroid 
lobectomy, isthmectomy and parathyroidectomy. In the three 
years which followed the patient received two courses of palliative 
radiotherapy, two thoracotomies for pulmonary metastatectomy, 
an extensive neck re-exploration and fashioning of a tracheostomy 
for aggressive local recurrence with invasion of the larynx. 
Introduction
Parathyroid carcinoma is a rare cause of primary 
hyperparathyroidism often resulting in severe hypercalcaemia. 
We report the case of a patient whose tumour caused severe 
hypercalcaemia apart from following an aggressive course with 
multiple local recurrences and metastasis. 
In one review of 4,239 patients with hyperparathyroidism, 2.1% 
had functioning parathyroid carcinomas.1  A systematic review of 
22,225 cases of primary hyperparathyroidism reported between 
1995 and 2003 revealed that parathyroid carcinoma accounted for 
0.74% of the cases.2
Parathyroid carcinoma accounts for 0.5 to 5% of cases 
of primary hyperparathyroidism although a relatively higher 
incidence has been reported in Italy and Japan.3 The average age 
of presentation is in the mid fifties4,5 but our patient presented in 
her early forties. 
The aetiology of parathyroid carcinoma is unclear although 
cases have been reported to develop within, or to coexist with, 
a parathyroid adenoma or a hyperplastic parathyroid gland. 
Parathyroid carcinomas have been associated with a prior history 
of neck irradiation, with end stage renal disease6 and with familial 
hyperparathyroidism, particularly the autosomal dominant 
variant7. 
Case report
We present the case of a 41 year old lady, with a past history of 
hyperprolactinaemia despite a normal looking pituitary on serial 
computed tomography (CT) and magnetic resonance imaging 
(MRI) scans.
She presented to hospital complaining of a tender lump over 
the left side of the neck, and another painful bony swelling over the 
left shin. She also reported recent dyspepsia, nausea, polyarthralgia, 
constipation and polyuria. On examination she appeared pale, 
dehydrated and was vomiting. A hard irregular left neck mass 
approximately 3 to 4 cm diameter was discovered in the absence 
of distinct palpable lymph nodes.
Urgent investigations revealed a severe hypercalcaemia and 
hypophosphataemia with a calcium level of 4.9mmol/l (reference 
range 2.15 - 2.55mmol/l) and a phosphate level of 0.77mmol/l 
(reference range 0.87 - 1.45mmol/l). Serum albumin was normal 
(47.3g/l) but parathyroid hormone (PTH) was elevated at 
1831.00pg/ml (reference range 12,00 - 72,00pg/ml).
Her prior history of hyperprolactinaemia and the newly 
diagnosed hyperparathyroidism, raised the possibility of Multiple 
Endocrine Neoplasia Type I (MEN-1).  The pituitary gland had 
however, appeared normal on serial scans. Additionally she denied 
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any family history of parathyroid disorders or MEN. Screening 
tests to definitively exclude MEN-1 gene mutations (11q13) were 
still pending at the time of writing.
Ultrasonography of the neck and technetium-99m-sestamibi 
scintigraphy with a subtraction thyroid scan using 123-I-iodine 
both indicated a mass of parathyroid origin while radiography of the 
left tibia confirmed a lytic bone lesion in keeping with the elevated 
serum alkaline phosphatase levels. Whole body scintigraphy yielded 
a metabolic super-scan compatible with a hyperactive parathyroid 
gland. 
The hypercalcaemia was treated with intravenous fluids and 
hydrocortisone, loop diuretics and pamidronate infusions achieving 
a serum calcium level of 3.19mmol/l pre-operatively. 
Surgery revealed a left-sided parathyroid tumor which was 
closely apposed to the oesophagus and invading the thyroid 
veins. The tumor (4 by 5 by 2cm) was excised together with the 
left thyroid lobe and thyroid isthmus to which it was adherent. 
Histology showed a parathyroid carcinoma (Fig. 1) infiltrating 
beyond the parathyroid and into the thyroid gland (Fig. 2).  In the 
immediate postoperative period, serum calcium levels plummeted 
necessitating high dose oral calcium and vitamin-D supplements 
which the patient continued to have on discharge. 
During the admission, CT scanning of the thorax and abdomen 
revealed a suspicious ovarian polycystic lesion for which she 
subsequently underwent a total abdominal hysterectomy. Histology 
revealed bilateral ovarian endometriosis. Concomitant biopsy of 
the tibial lesion confirmed a brown tumour of bone which visibly 
decreased in size and disappeared after the neck surgery relieved 
hyperparathyroidism and hypercalcaemia. 
Six months post surgery, calcium levels began to rise sharply 
again suggesting the existence of a metastatic focus. CT scanning of 
the lady’s chest in fact showed three well circumscribed right 
pulmonary lesions which were excised at thoracotomy.  Histology 
confirmed metastatic deposits of parathyroid carcinoma (Fig. 
3).  Once again there was immediate and significant relief of 
hypercalcemia postoperatively.
The following year, examination of the patient’s neck revealed 
a palpable right upper cervical lymph node.  Following radiological 
studies, a twenty-day course of radiotherapy to the anterior 
cervical region was administered. During this period she required 
aggressive management of hypercalcaemia as radiation-induced 
tumour apoptosis led to parathyroid hormone release.  There was 
an excellent response to radiotherapy with a significant reduction 
in tumour size and eventual resolution of the hypercalcaemia.  At 
serial follow-up, hypercalcaemia recurred off calcium supplements 
and serum PTH levels increased to 317.00pg/ml. A CT-thorax 
disclosed a residual lesion in the right lung which was resected 
during a second thoracotomy and pulmonary metastasis was again 
confirmed on histology.  
Despite the metastatectomies,  the hypercalcaemia failed 
to settle completely and her requirements for intravenous 
pamidronate increased.  A parathyroid scan showed no abnormal 
focus of tracer accumulation in the neck, thorax, lung or bones and 
a thyroid scintigram revealed an enlarged right thyroid lobe with 
relatively homogeneous tracer uptake throughout. However, 
approximately five months later, she complained of hoarseness. On 
examination irregular enlargement of the residual right hemithyroid 
was palpable and an ultrasound of the neck revealed an enlarged 
right thyroid lobe containing multiple solid nodules of up to 4cm 
in diameter. Vocal cord dysfunction was ruled out and the patient 
referred for surgical neck exploration.
Intraoperatively, metastatic parathyroid carcinoma was seen 
to involve both anterior jugular veins (Fig. 4), the venous plexus 
of the right strap muscles, and the veins of tissues anterior to the 
hyoid bone, thyroid gland, cricoid cartilages and anterior trachea. 
This entire tissue mass was submitted for histology and infiltration 
by parathyroid carcinoma was established.  Early postoperative 
hypocalcaemia was treated with oral calcium supplements but 
within a few weeks hypercalcaemia developed and the patient was 
commenced on cinacalcet with good effect.
Her hoarseness worsened during the weeks which followed 
surgery and a CT scan of the neck revealed a soft tissue mass invading 
Figure 1: High power view of parathyroid carcinoma 
showing sheets of cells with abundant, pale, rather granular 
cytoplasm; central nuclei with anisonucleosis; clumped 
chromatin and prominent nucleoli. A mitotic count of four 
mitotic figures per ten high power fields was observed in the 
tumour (Original magnification: x400)
Figure 2: Multiple, partly circumscribed, tumour nodules 
infiltrating the thyroid parenchyma of the left thyroid lobe. 
(Original magnification: x100) 
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the larynx (Fig. 5) and the recurrent laryngeal nerve. Eventually 
she developed significant stridor and laryngoscopy confirmed a 
right vocal cord paralysis for which an urgent tracheostomy was 
performed. Meanwhile the oncologist initiated a protracted course 
of palliative radiotherapy to the neck with good response. Despite 
the dose of cinacalcet having been increased to 90mgs twice daily, 
tumour cell apoptosis secondary to radiotherapy has led to the need 
for repeated sessions of intravenous hydration and pamidronate 
during the time that she was undergoing radiotherapy. The patient 
was left with a permanent tracheostomy and continued regular 
monitoring of her serum calcium levels and medical management 
as necessary.
Multidisciplinary and multimodality treatment by an endocrine, 
surgical, ENT and oncology team have enabled this lady to survive 
an aggressive parathyroid carcinoma for three and a half years.
Discussion
Clinical features
Parathyroid carcinoma classically presents with hypercalcaemia-
related symptoms rather than by tumour invasion.8 Signs and 
symptoms of hypercalcaemia include anorexia, lethargy and weight 
loss, nausea, vomiting, polyuria and polydipsia with our patient 
demonstrating most of these at presentation. Skeletal involvement 
is common with features of hyperparathyroid bone disease resulting 
in bone pain and pathological fractures.  Radiological hallmarks 
include osteitis fibrosa cystica, subperiosteal bone resorption, salt-
and-pepper skull and absent lamina dura.  
Renal involvement is a frequent feature and renal colic as 
a consequence of nephrolithiasis is an important presenting 
complaint.  Nephrocalcinosis and impaired glomerular filtration 
may lead to renal insufficiency in such patients. Pancreatitis and 
peptic ulcer disease secondary to the relentless hypercalcaemia may 
complicate the picture further. Our patient did not exhibit any of 
these symptoms or signs. 
There have been isolated reports of nonfunctional parathyroid 
carcinomas. These often present with metastatic disease and tend 
to be associated with a worse prognosis.9 Serial PTH estimates from 
the time of presentation to the time of starting cinacalcet confirmed 
that our patient was suffering from a functional parathyroid 
carcinoma. 
Features favouring parathyroid carcinoma as opposed to 
primary hyperparathyroidism, include the coexistence of renal and/
or skeletal involvement,4 a palpable neck mass (present in 30-70% 
of patients with parathyroid carcinoma) and recurrent laryngeal 
nerve involvement. Hypercalcaemia in parathyroid carcinoma tends 
to be more severe and recalcitrant to treatment (>3.5mmol/L in 
65-75% of patients). In one study examining the relation between 
hypercalcaemia and parathyroid carcinoma however, the positive 
predictive value and sensitivity of hypercalcaemia were found 
to be 14% and 56% only, respectively. On the other hand, PTH 
levels and tumour weight emerged as the more reliable surrogate 
indicators of parathyroid carcinoma. A tumour weight in excess of 
2.5g, strongly favours a diagnosis of parathyroid carcinoma over 
that of adenoma.3 Serum hormone levels tend to hover at about 
10.3 times the upper limits of normal in parathyroid carcinomas 
as was the case in our patient. In contrast, mean PTH levels in 
benign primary hyperparathyroidism will usually reach 2.6 times 
the normal values. 
Parathyroid carcinoma is slow growing and metastasizes late, 
with the most frequent sites of deposits being the lung (40%), 
cervical lymph nodes (30%), and liver (10%). Less commonly, 
metastases to bone, pleura, pancreas or pericardium may occur. 
Diagnosis
The diagnosis of parathyroid carcinoma is often difficult to 
establish because its clinical features are similar to those of benign 
primary hyperparathyroidism. Fine needle aspiration is not useful 
in establishing the diagnosis which is clinched only after confirming 
infiltration beyond the tumour capsule.  
The Schantz and Castleman histological criteria10 have been 
used to facilitate differentiation of parathyroid carcinoma from 
adenoma. Like adenoma, parathyroid carcinoma is usually 
composed of uniform sheets of cells. Cytologic features of carcinoma 
include atypical mitotic figures, nuclear pleomorphism and nuclear 
enlargement. Architectural features of carcinoma include the 
presence of a thick fibrous capsule, intratumoral fibrous trabeculae 
Figure 3: Metastatic parathyroid carcinoma in the right 
lung. The tumour (right side of image) has a solid growth 
pattern; some nesting of malignant cells is also observed. 
(Original magnification: x200)
Figure 4: Parathyroid carcinoma in jugular vein.
Tumour (lower right) present in the lumen of the external 
jugular vein. Part of the muscle wall of the vein is seen on the 
upper left side of the image. (Original magnification: x200)
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and a trabecular or rosette-like tumour cell arrangement. The 
criteria upon which a definitive diagnosis of parathyroid carcinoma 
can be made include capsular invasion, vascular invasion, local 
invasion of contiguous structures and lymph node or distant 
metastases. 
Bondeson et al. noted that that presence of macronucleoli, 
necrosis and mitotic activity in excess of 5/50 per high power field, 
generally correlated with more aggressive clinical carcinomas.11 
DNA aneuploidy has also been associated with adverse histologic 
features and a worse prognosis12 but not invariably, since euploid 
tumours may also turn out to be clinically aggressive.13
Parathyroid carcinomas like adenomas express pancytokeratin 
and neuroendocrine markers such as chromogranin-A. Histology 
in our patient showed immunopositivity for these stains. 
Chromogranin-A or Parathyroid Secretory Protein-1 is a member of 
the chromogranin/secretogranin (granins) family of neuroendocrine 
secretory proteins, located in the secretory vesicles of neurons 
and endocrine cells where it stabilizes the soluble portion of the 
neurosecretory granules and plays a role in hormonal secretion.14 
Calcitonin and Thyroid Transcription Factor-1 are expressed by 
medullary thyroid carcinomas but not by parathyroid carcinomas 
and can serve to tell the two apart.
PTH immunopositivity affirms the parathyroid origin of the 
tumour whereas proliferation markers serve a limited role in 
differentiating parathyroid carcinomas from adenomas. Ki-67 
is one such marker staining cells which are actively cycling. A 
higher proportion of Ki-67-positive cells will usually be present 
in a carcinoma as opposed to an adenoma because of the higher 
proportion of proliferating cells in the former, but discrimination 
between the two on this basis alone is difficult because considerable 
overlap exists.15,16 Cyclin D1 is another proliferation marker 
which also demonstrates higher expression in carcinomas than 
adenomas.17
Immunostaining with Ki-67 was not performed in our patient 
because evidence of thyroid gland and vascular invasion at the time 
of presentation had made it already amply clear that the tumour 
was malignant. 
Diagnosis of parathyroid carcinoma also requires radiological 
investigations such as ultrasonography, CT, MRI and scintigraphy 
for the purpose of localization and diagnosis. 
The low incidence of parathyroid carcinoma means that no 
American Joint Committee on Cancer staging system has yet been 
formulated with respect to this disease. Furthermore, neither tumor 
size nor lymph node status appear to be important prognostic 
markers for this tumor. It is possible to stratify patients based 
on whether they have localized or metastatic disease at the time 
of presentation. Localized disease would involve the parathyroid 
gland with or without invasion of adjacent tissues while metastatic 
cancer implies spread beyond the tissues adjacent to the involved 
parathyroid gland(s).18,19
Molecular pathogenesis
Mutations of several genes have been implicated in 
the pathogenesis of parathyroid carcinoma, including the 
Hyperparathyroidism 2 gene (HRPT2), the oncogene Cyclin 
Dl (CD1) or Parathyroid Adenoma 1 (PRAD1),20 and the tumor 
suppressor genes Retinoblastoma and p53.21
CD1 or PRAD1 is a protoncogene (11q13) whose protein 
product is a cell cycle regulator.22 CD1 gene amplification has been 
implicated in the pathogenesis of numerous tumors with Hsi et al. 
demonstrating that out of 65 patients with parathyroid tumors, 
over-expression of CD1 occurred in 18%.23 Although this study 
included only three patients with parathyroid carcinoma, two of the 
these exhibited tumors that stained very strongly for CD1, raising 
the possibility that the frequency of CD1 over-expression may be 
greater in carcinoma than previously assumed. 
There is increasing evidence to suggest that loss of expression 
of the HRPT2 gene (1q21-q32) which customarily encodes the 
parafibromin protein, is also strongly associated with parathyroid 
carcinomas. The precise function of parafibromin is still being 
elucidated but it appears to regulate transcriptional control and 
inhibit cellular proliferation. Methylation of the HRPT2 promoter 
may lead to HRPT2 gene inactivation potentially giving rise to 
parathyroid carcinomas.24
Inactivating germline mutations in the HRPT2 gene give rise 
to an autosomal dominant type of familial hyperparathyroidism 
called the Hyperparathyroidism-Jaw Tumor syndrome (HPT-JT).25 
These patients are predisposed to mandibular or maxillary ossifying 
fibromas, cystic and neoplastic renal lesions such as Wilm’s tumors, 
and parathyroid neoplasias such as recurrent parathyroid adenomas 
with an increased propensity for parathyroid cancer. Importantly, 
in HPT-JT, all parathyroid glands are at risk for tumor development 
but the tumors can occur asynchronously over many years.
A subset of patients with sporadic parathyroid cancer may 
Figure 5: Computed Tomographic scan of the neck 
in February 2009. There is a solid mass (black arrow) 
measuring 3-3.5cm on the right extending from the level 
of the hyoid to the lower margin of the thyroid cartilage.  
The mass is invading right parapharyngeal region and 
destroying the right wing of the thyroid cartilage. It is also 
compressing the pharynx and the proximal part of the 
trachea 
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have clinically unsuspected germline HRPT2 mutations26 which, 
if confirmed, would have important therapeutic implications 
for affected subjects but would also allow for early detection or 
prevention of parathyroid malignancy in family members. For this 
reason genetic testing for germline HRPT2 mutations is clinically 
indicated in most patients with sporadic parathyroid carcinoma. 
Surgical management
The most effective treatment for parathyroid carcinoma is 
surgical and consists of en-bloc resection of the tumor mass with 
care to avoid rupture of the capsule, as this increases the chance of 
local seeding.1,21 Often, resection of the ipsilateral thyroid lobe and 
isthmus and dissection of the tracheoesophageal groove may be 
necessary. The recurrent laryngeal nerve may have to be exported 
if found to be involved. Locally involved lymph nodes should be 
excised but radical neck dissection is indicated only when there is 
spread to the anterior cervical nodes.27
Since the initial intervention offers the best prospect for cure, 
pre-operative suspicion of parathyroid carcinoma and careful 
exploration of the four parathyroid glands is key.  Frozen section for 
histology is often resorted to for intra-operative recognition. 
One well recognized surgical complication in patients in whom 
the tumor is completely excised is the development of the “hungry 
bone syndrome.”28 The sudden postoperative withdrawal of PTH 
induces abrupt cessation of osteoclastic bone resorption without 
affecting osteoblastic activity. Consequently, an increased bone 
uptake of calcium, phosphate and magnesium is observed. 
Risk factors for the syndrome include:  large parathyroid 
adenomas, age > 60 years, and high pre-operative PTH levels, 
calcium and alkaline phosphatase. In high risk individuals careful 
vigilance for clinical symptoms of hypocalcaemia and close follow 
up of laboratory parameters are warranted during the immediate 
postoperative period. Treatment is with large doses of oral or 
intravenous calcium and oral calcitriol, at least initially.
Local recurrence as well as distant metastases occurring due 
to lymphatic and haematogenous spread may and do occur in 
parathyroid carcinomas. Since radiotherapy and chemotherapy 
are generally ineffective,6 surgery may also have a role in the 
palliative management of recurrent or metastatic disease, through 
the extirpation of lesions in the neck, lungs or liver providing 
symptomatic relief and reducing serum calcium and hormone 
levels in most patients.29 The potential morbidity caused by these 
re-operations must be borne in mind.
Adjuvant therapy
Parathyroid carcinoma is not a radiosensitive tumour and the 
role of radiotherapy is generally restricted to neck irradiation after 
surgery for recurrence, in order to prevent re-growth. Use of either 
radiotherapy or chemotherapy should be considered only when a 
patient is not a candidate for surgery and hypercalcaemia cannot 
be controlled.
The role of chemotherapy in the management of parathyroid 
carcinoma is limited although there are scant reports of success 
with synthetic oestrogens, 5-fluorouracil, cyclophosphamide and 
dacarbazine-containing regimes. There have been reports supporting 
the use of immunotherapy in carcinomas where immunisation with 
human, modified human and bovine PTH peptides stimulated the 
production of autoantibodies against human PTH giving rise to 
PTH-antibody immune complexes. This strategy has been successful 
in reducing hypercalcaemia, improving clinical status30 and in one 
case it was even shown to reduce tumour load.6 
Control of intractable hypercalcaemia
When the tumor is no longer amenable to surgical intervention, 
treatment becomes limited to the control of hypercalcaemia through 
hydration, calcimimetic agents or intravenous bisphosphonates. 
Calcimimetics increase the sensitivity of the parathyroid gland 
calcium-sensing receptor.31,32 The longer-acting calcimimetic, 
cinacalcet (Sensipar®), has been approved by the United 
States Food and Drug Administration for the treatment of 
secondary hyperparathyroidism associated with renal failure and 
hypercalcaemia associated with parathyroid cancer.
Cinacalcet allosterically enhances the action of calcium ions 
at the parathyroid gland calcium receptors which belong to the 
superfamily of G protein-coupled receptors. Resulting from the 
effect at the parathyroid gland calcium receptors, serum levels of 
calcium decline.33
Bisphosphonates such as pamidronate (approved by the 
United States Food and Drug Administration for hypercalcaemia 
of malignancy) have been reported to improve hypercalcaemia in 
individual cases of parathyroid carcinoma.34,35 One might predict 
that the more potent zoledronic acid, which is approved for use 
in hypercalcaemia of malignancy,36 would also be effective in the 
treatment of hypercalcaemia due to parathyroid carcinoma.
Prognosis
Hypercalcaemia is the principal cause of morbidity and 
mortality from parathyroid carcinoma. The carcinomas grow 
slowly in most patients, but can occasionally be aggressive. The 
disease typically follows one of three courses: one third of patients 
are cured at initial or follow-up surgery, one third experience a 
recurrence after a prolonged disease-free survival but may be cured 
with re-operation, and one third experience a short and aggressive 
course.37
Parathyroid carcinomas with locoregional extension at initial 
surgery have potential for recurrence. Aggressive surgical resection 
of recurrent carcinoma is beneficial for palliation of hypercalcaemia 
in selected patients. Ki-67 staining may be a valuable prognostic 
indicator as tumors with indices greater than 10% are more likely 
to recur in the early postoperative period. In an analysis of several 
studies, the combined 5- and 10-year survival rates for patients 
with parathyroid carcinomas varied from 50 to 70 and 13 to 35 
percent respectively,1 with a mean survival time of 6 to 7 years.1 
Conclusion
Albeit the morbidity imparted by the numerous surgical 
interventions and the more recent tracheostomy, three years since 
her original diagnosis, a concerted and persistent multidisciplinary 
effort has meant that our young patient is still capable of enjoying a 
reasonably good quality of life with her family and children. 
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Erratum
The following case report, published in March 2010, 
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2010;22(1):34-6.
Acknowledgements
Dr. James Degeatano, Consultant Histopathologist, 
Department of Pathology, Mater Dei Hospital, Malta for 
the interpretation of the histology and preparation of the 
biopsy pictures.
Dr.  Ali Safraz, Consultant Histopathologist, St. James’ 
Hospital, Malta for the original histology report and the 
biopsy specimen.
